Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 170,495,536
  • Shares Outstanding, K 2,317,460
  • Annual Sales, $ 50,135 M
  • Annual Income, $ 7,703 M
  • 36-Month Beta 0.76
  • Price/Sales 3.50
  • Price/Cash Flow 10.06
  • Price/Book 2.47

Price Performance

See More
Period Period Low Period High Performance
1-Month
73.21 +0.49%
on 06/19/18
77.47 -5.03%
on 05/21/18
-3.49 (-4.53%)
since 05/18/18
3-Month
73.21 +0.49%
on 06/19/18
82.42 -10.74%
on 04/10/18
-7.66 (-9.43%)
since 03/19/18
52-Week
73.21 +0.49%
on 06/19/18
94.19 -21.89%
on 01/26/18
-7.87 (-9.66%)
since 06/19/17

Most Recent Stories

More News
Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis

Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of new evidence that Cosentyx® (secukinumab) significantly slows the progression of joint structural damage...

NVS : 73.57 (-0.70%)
Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis

Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis

LLY : 86.82 (+0.82%)
NVS : 73.57 (-0.70%)
HLUYY : 72.6500 (-0.62%)
GSK : 41.04 (-0.56%)
Teva to Discontinue a Fremanezumab Study on Cluster Headache

Teva decides to halt a phase III study, evaluating fremanezumab for the treatment of chronic cluster headache, following an interim analysis, which anticipates that the study is unlikely to meet its endpoint....

ALDR : 17.80 (+3.19%)
NVS : 73.57 (-0.70%)
TEVA : 24.05 (-0.70%)
AMGN : 186.19 (+1.22%)
Novartis Announces Positive Data on CAR-T Therapy, Kymriah

Novartis (NVS) announces positive results on Kymriah from the JULIET TRIAL in patients with relapsed or refractory diffuse large B-cell lymphoma.

QURE : 38.22 (+1.59%)
ONCE : 82.88 (+8.07%)
NVS : 73.57 (-0.70%)
GILD : 70.94 (+2.72%)
Large Cap Pharma Stock Outlook: Short-Term Struggle Likely

Large Cap Pharma Stock Outlook: Short-Term Struggle Likely

LLY : 86.82 (+0.82%)
NVS : 73.57 (-0.70%)
HLUYY : 72.6500 (-0.62%)
GSK : 41.04 (-0.56%)
Novartis International AG: Alcon AcrySof(R) IQ PanOptix(R) trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery

Novartis International AG / Novartis International AG: Alcon AcrySof(R) IQ PanOptix(R) trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery . Processed...

NVS : 73.57 (-0.70%)
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL

Novartis International AG / Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL . Processed and transmitted by Nasdaq...

NVS : 73.57 (-0.70%)
Roche Announces Positive Data on Gazyva and MS Drug Ocrevus

Roche (RHHBY) announced positive long-term data on leukemia drug Gazyva and MS drug Ocrevus.

NVS : 73.57 (-0.70%)
RHHBY : 26.5300 (+0.53%)
AMGN : 186.19 (+1.22%)
BIIB : 292.04 (+1.01%)
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life

Many patients with the rare blood disorder immune thrombocytopenia (ITP) find the disease has a negative impact on their everyday quality of life, according to interim results of a Novartis survey, called...

NVS : 73.57 (-0.70%)
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life

Novartis International AG / Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life . Processed and transmitted by Nasdaq Corporate...

NVS : 73.57 (-0.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade NVS with:

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Key Turning Points

2nd Resistance Point 74.24
1st Resistance Point 73.90
Last Price 73.57
1st Support Level 73.22
2nd Support Level 72.88

See More

52-Week High 94.19
Fibonacci 61.8% 86.18
Fibonacci 50% 83.70
Fibonacci 38.2% 81.22
Last Price 73.57
52-Week Low 73.21

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar